Navigation Links
Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran(TM) System to Suppress Tumor-Induced Angiogenesis in Mice
Date:10/24/2007

tly to tumor vasculature and tumor cells," said Mohammad Azab, M.D., president and chief executive officer of Intradigm. "The targeting of the VEGF pathway with RNAi represents a novel approach for anti-angiogenesis-based therapeutics, and with the tumor selectivity offered by our TargeTran(TM) system, we believe we are developing an innovative therapeutic candidate that may possess efficacy and/or safety advantages over existing or other anti-angiogenic agents in development."

ICS-283 is currently in preclinical development for a variety of cancer indications and the company expects to initiate clinical development of this candidate in 2008. The findings presented today support data from several other in vivo models, including xenograft models of different cancers, which have confirmed an RNAi-mediated anti-angiogenic effect following systemic administration similar to VEGF antibody. VEGF, as an established target in the treatment of cancer, provides a clear clinical development path to validate the success of Intradigm's systemic delivery of siRNA in man.

ABOUT INTRADIGM'S siRNA DELIVERY TECHNOLOGY

To address the issue of effective and targeted delivery of RNAi therapeutics, Intradigm has developed its proprietary RNAi Nanoplex(TM) technology, a powerful combination of advanced delivery systems. The RNAi Nanoplex(TM) technology is a multi-component delivery vector that carries active siRNA molecules in its core and in its targeted form (TargeTran(TM)) carries a ligand attached to its surface for specific tissue targeting. This platform is unique in its ability to offer tissue specific targeting of siRNA and intracellular delivery against the intracellular machinery of the target tissue. In addition, Intradigm also developed the PolyTran(TM) delivery system, a novel biodegradable polycation polymer that also shows great promise as an RNAi delivery system. Intradigm believes that this Nanoplex(TM) platform is one of the most versatile siRNA systemi
'/>"/>

SOURCE Intradigm Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , August 1, 2014 ... Market by Type (Traditional Wound Closure, Anti infective), Basic ... (Artificial Skin & Skin Substitutes), Pressure Relief Devices, ... MarketsandMarkets, the global Wound Care Market is expected to ... in 2014, growing at a CAGR of 3.2% ...
(Date:8/1/2014)... Aug. 1, 2014  NxStage Medical, Inc. (Nasdaq: ... announced that Jeffrey H. Burbank , Chief Executive Officer, ... at the 34 th Annual Canaccord Genuity Growth Conference ... , on Wednesday, August 13 th at 4:30 ... available at http://ir.nxstage.com/ .  About NxStage ...
(Date:8/1/2014)... , Aug. 1, 2014  Neuland Laboratories ... active pharmaceutical ingredients (APIs), complex intermediates ... located in 85 countries, today announced financial results ... 2015, ended June 30, 2014. "Neuland,s ... work flow re-prioritization to accommodate certain customer needs, ...
Breaking Medicine Technology:Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3
... AUSTIN, Texas, May 22, 2012 SmallCapVoice.com, Inc. ... Medical Marijuana, Inc. (PINKSHEETS: MJNA) is now available. ... . Recent company activity and highlights: ... approximately $1.21 million on gross revenues of $1.79 ...
... Laboratory, Inc. (HDL, Inc.), a CAP accredited leader in ... with a non-restricted educational grant to further its mission ... the United States. In addition to the grant, HDL, ... of the 2012 Annual Scientific Sessions in Scottsdale, Arizona ...
Cached Medicine Technology:Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With SmallCapVoice.com in Quarterly Series 2Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With SmallCapVoice.com in Quarterly Series 3Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With SmallCapVoice.com in Quarterly Series 4Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona 2
(Date:8/1/2014)... Cannabis use among young people has spiked, with ... used marijuana at least once and 17 percent admitting to ... Drugs, Say ‘Yes to Life,’ volunteers from the Church of ... with factual information about drugs, to help reverse this alarming ... to Drugs, Say ‘Yes’ to Life,” volunteers have distributed 40,000 ...
(Date:8/1/2014)... School of Medicine in St. Louis helps explain why ... are more harmful than similar tumors in females. For ... diagnosed twice as often in males, who suffer greater ... long. , The researchers found that retinoblastoma protein (RB), ... less active in male brain cells than in female ...
(Date:8/1/2014)... Barbara Bronson Gray HealthDay Reporter ... obese and work in manufacturing jobs may have significantly less endurance ... a study of 32 people -- half were obese, half were ... times that were about 60 percent longer. Obesity also was ... Being older -- 50 to 65 years of ...
(Date:8/1/2014)... 1, 2014 (HealthDay News) -- Almost 140 people ... transportation in the United States. But there ... catastrophes, Dawne Gardner, injury prevention coordinator at Cincinnati ... said in a medical center news release. ... to school, it,s important for parents and children ...
(Date:8/1/2014)... MN (PRWEB) August 01, 2014 Summer is ... are most active during the summer, and they can be ... Minnesota is ready to help all their customers get rid ... between 3,000 and 6,000 eggs in the summer, which is ... to live in tall grass and woodland areas and carry ...
Breaking Medicine News(10 mins):Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Study reveals one reason brain tumors are more common in men 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:Expert Offers School Bus Safety Tips 2Health News:Tis the Season for Tick Prevention 2
... was honored for ecommerce expertise when President Michael Del Chiaro was ... the highly respected Entrepreneur magazine. , ... Fort Scott, ... for the interview based on his proven success in building a ...
... Feature ,Leave It To Beaver, Star Jerry MathersJACKSON, Miss., ... Express, bus tour will be stopping in Mississippi the ... state in order to help uninsured and financially-struggling Mississippians ... free or nearly free. With the unemployment rate in ...
... March 5 Ranbaxy Pharmaceuticals Inc. (RPI), a ... announced today that RLL has received approval from ... and market Quinapril Hydrochloride & Hydrochlorothiazide (Quinapril + ... The Application for the drug was submitted by ...
... every day for six months were able to increase the ... their erectile function by up to 36%, according to an ... BJU International . , Researchers from San Giovanni Battista Hospital ... this treatment could provide a viable alternative to surgery, as ...
... March 4, 2009Overweight children and adolescents, with the active ... weight by following the Seven Steps to Success described ... a journal published by Mary Ann Liebert, Inc. ... , A team of experts that includes ...
... BioFortis wins another award for its Labmatrix(TM) ... institutional clients worldwide for translational research, biomarker ... 5 /PRNewswire/ -- BioFortis, Inc., ... used by pharmaceutical and institutional clients, today ...
Cached Medicine News:Health News:My1Stop.com President Michael Del Chiaro Interviewed by Entrepreneur.com for ecommerce Expertise 2Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 4Health News:Ranbaxy Secures Final FDA Approval for Quinapril Hydrochloride + Hydrochlorothiazide Tablets 2Health News:Penile extender increased flaccid length by almost a third says independent clinical study 2Health News:7 steps to successful child and adolescent weight loss 2Health News:BioFortis Wins Best Product Award in Discovery Informatics at the 2009 Molecular Medicine Tri-Conference 2
... ready-to-use solutions ideal for a wide range ... prepared with 18 megOhm water, filtered using ... sterile bottles., Reliable - Manufactured according ... lot-to-lot consistency. , High Quality - ...
12% Tryptone, 24% Yeast Extract, 4.0% Glycerol. Supplied with 1 liter of 10x phosphate buffer (0190-1L)....
1.2% Tryptone, 2.4% Yeast Extract, 0.4% Glycerol, with 100ml of 10x Phosphate buffer supplement (0190-01)....
10% Casein digest (NZ amine), 5.0% Sodium Chloride, 5.0% Yeast Extract....
Medicine Products: